Free Trial
NASDAQ:TRVN

Trevena 8/8/2024 Earnings Report

Trevena logo
$1.28 +0.09 (+7.11%)
As of 04/29/2025 01:33 PM Eastern

Trevena EPS Results

Actual EPS
-$0.23
Consensus EPS
-$9.25
Beat/Miss
Beat by +$9.02
One Year Ago EPS
N/A

Trevena Revenue Results

Actual Revenue
$0.33 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Trevena Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Trevena's next earnings date is estimated for Wednesday, April 30, 2025, based on past reporting schedules.

Conference Call Resources

Trevena Earnings Headlines

Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com
What if America bought gold like it used to?
History Says Gold Wins When This Signal Flashes — and It’s Flashing Now Every time the Buffett Indicator has hit extreme levels, stocks have crashed — and gold has dominated the decade that followed. Today, the Buffett Indicator is at its highest reading in history… and Buffett himself is sitting on an unprecedented $325 billion cash pile. Sources say he’s preparing to deploy it — not into stocks, but into gold. Garrett Goggin has uncovered which gold company could be his next big move.
JMP Securities downgrades Trevena (TRVN) to a Hold
See More Trevena Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Trevena? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Trevena and other key companies, straight to your email.

About Trevena

Trevena (NASDAQ:TRVN), a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

View Trevena Profile

More Earnings Resources from MarketBeat